Volume | 1,220 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Revelation Biosciences Inc | REVB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.15 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
24 | 1,220 | - | 1.7801 - 39.30 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
04:53:42 | formt | 132 | $ 2.29 | USD |
Revelation Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
4.2k | 209.91k | - | 0 | -120k | -0.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Revelation Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical REVB Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.36 | 2.5199 | 1.7801 | 2.03 | 67,626 | -0.07 | -2.97% |
1 Month | 2.47 | 2.96 | 1.7801 | 2.45 | 68,430 | -0.18 | -7.29% |
3 Months | 12.20 | 25.26 | 1.7801 | 5.83 | 422,130 | -9.91 | -81.23% |
6 Months | 20.244 | 25.26 | 1.7801 | 8.00 | 273,829 | -17.95 | -88.69% |
1 Year | 35.10 | 39.30 | 1.7801 | 17.81 | 237,410 | -32.81 | -93.48% |
3 Years | 8,799.00 | 10,237.50 | 1.7801 | 982.33 | 1,290,279 | -8,796.71 | -99.97% |
5 Years | 8,799.00 | 10,237.50 | 1.7801 | 982.33 | 1,290,279 | -8,796.71 | -99.97% |
Revelation Biosciences Description
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. |